Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the supplement, Fisetin, can be used as a
treatment option for common variable immunodeficiency (CVID) by comparing its efficacy to
placebo.